Clinical Trials Browser

PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy

NCT06136650 2026-04-15

MK-5684-004

Phase 3 Recruiting

1,314 enrolled

Genitourinary

Prostatic Neoplasms

NCT02960022 2026-04-13

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Phase 2 Recruiting

900 enrolled

Genitourinary

Prostatic Neoplasms

NCT05818683 2026-04-13

A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

Phase 1 Recruiting

300 enrolled

Genitourinary

Metastatic Castration-resistant Prostate Neoplasms

NCT05901649 2026-04-13

ArtemisPRO

Active not recruiting

504 enrolled

Genitourinary

Metastatic Hormone-sensitive Prostate Cancer

NCT06863272 2026-04-13

IDeate-Prostate02

Phase 1/2 Recruiting

360 enrolled

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms, Castration-Resistant

NCT07406282 2026-04-09

Double-DARE

Recruiting

1,400 enrolled

Genitourinary

Prostatic Neoplasms

NCT06136624 2026-04-08

OMAHA-003

Phase 3 Recruiting

1,310 enrolled

Genitourinary

Prostate Cancer Metastatic

NCT07287150 2026-04-08

InavoPC

Phase 2 Recruiting

100 enrolled

Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT03395197 2026-04-07

TALAPRO-2

Phase 3 Active not recruiting

1,054 enrolled 21 charts 2 FDA

mCRPC

NCT04821622 2026-04-07

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

Phase 3 Active not recruiting

599 enrolled

Genitourinary

Prostatic Neoplasms

NCT05112965 2026-04-06

An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)

Phase 3 Active not recruiting

49 enrolled

Tumor-Agnostic

Neoplasms

NCT06120491 2026-04-03

EvoPAR-PR01

Phase 3 Recruiting

1,800 enrolled

Genitourinary

Prostatic Neoplasms

NCT03899155 2026-04-01

Pan Tumor Rollover Study

Phase 2 Recruiting

1,500 enrolled

Tumor-Agnostic

Neoplasms

NCT04221542 2026-03-30

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

Phase 1 Recruiting

479 enrolled

Genitourinary

Bites and Stings, Prostatic Neoplasms

NCT07028853 2026-03-30

MEVPRO-3

Phase 3 Recruiting

1,000 enrolled

Genitourinary

Prostatic Neoplasms

NCT04191096 2026-03-20

KEYNOTE-991

Phase 3 Active not recruiting

1,251 enrolled 15 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body

Clinical Trials

China ARCHES

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

MK-5684-004

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

ArtemisPRO

IDeate-Prostate02

Double-DARE

OMAHA-003

InavoPC

TALAPRO-2

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)

EvoPAR-PR01

Pan Tumor Rollover Study

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

MEVPRO-3

KEYNOTE-991